TUBB3 response to PI3K/AKT pathway inhibitors was reported to be either upregulated or downregulated in various cancer types (Levallet et al., 2012; McCarroll et al., 2015; Sekino et al., 2019; Martinez et al., 2020). This evidence concerns the gene TUBB3 and cancer.